- Home
- ESRT vs MESO Comparison
ESRT vs MESO Comparison
Compare ESRT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- MESO
- Stock Information
- Founded
- ESRT 2011
- MESO 2004
- Country
- ESRT United States
- MESO Australia
- Employees
- ESRT N/A
- MESO N/A
- Industry
- ESRT Real Estate Investment Trusts
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESRT Real Estate
- MESO Health Care
- Exchange
- ESRT Nasdaq
- MESO Nasdaq
- Market Cap
- ESRT 1.2B
- MESO 1.3B
- IPO Year
- ESRT 2013
- MESO N/A
- Fundamental
- Price
- ESRT $7.78
- MESO $18.05
- Analyst Decision
- ESRT Hold
- MESO Buy
- Analyst Count
- ESRT 2
- MESO 2
- Target Price
- ESRT $10.65
- MESO $24.00
- AVG Volume (30 Days)
- ESRT 1.5M
- MESO 285.6K
- Earning Date
- ESRT 10-29-2025
- MESO 08-28-2025
- Dividend Yield
- ESRT 1.81%
- MESO N/A
- EPS Growth
- ESRT N/A
- MESO N/A
- EPS
- ESRT 0.24
- MESO N/A
- Revenue
- ESRT $763,746,000.00
- MESO $17,198,000.00
- Revenue This Year
- ESRT $2.27
- MESO $288.50
- Revenue Next Year
- ESRT $3.04
- MESO $167.17
- P/E Ratio
- ESRT $32.38
- MESO N/A
- Revenue Growth
- ESRT 1.14
- MESO 191.39
- 52 Week Low
- ESRT $6.56
- MESO $7.09
- 52 Week High
- ESRT $11.62
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- ESRT 55.39
- MESO 63.51
- Support Level
- ESRT $7.72
- MESO $17.10
- Resistance Level
- ESRT $7.87
- MESO $18.91
- Average True Range (ATR)
- ESRT 0.16
- MESO 0.54
- MACD
- ESRT 0.02
- MESO 0.18
- Stochastic Oscillator
- ESRT 82.57
- MESO 75.65
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.